KYNB
KYNTRA BIO, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2025(8Q snapshot) | 3Q | $9.88 | $6.83 | -31% |
| Two Sigma Investments | Q3 2025(8Q snapshot) | 3Q | $9.48 | $6.83 | -28% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors | Q4 2025 | Q2 2026 | → $6.82 | -22% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at KYNTRA BIO, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 17, 2026 — the most recent Form 4 on file — not from today.
- Form 40001646395-26-000002Jun 17, 2026
- Form 40001190642-26-000004Jun 17, 2026
- Form 40001364719-26-000004Jun 17, 2026
- Form 40001420987-26-000004Jun 17, 2026
- Form 40001815638-26-000009Jun 9, 2026
- Form 40002040705-26-000005Jun 9, 2026
- Form 4/Aamend0001815638-26-000007May 19, 2026
- Form 40001815638-26-000005May 18, 2026
- Form 40001815638-26-000003Mar 10, 2026
- Form 40002040705-26-000003Mar 10, 2026
- Form 40001815638-26-000002Feb 5, 2026
- Form 40002040705-26-000002Feb 5, 2026
- Form 40002040705-25-000002Dec 9, 2025
- Form 40001815638-25-000005Dec 9, 2025
- Form 40001815638-25-000004Nov 17, 2025
Fundamentals
XBRL · KYNTRA BIO, INC.Annual figures sourced directly from KYNTRA BIO, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for KYNTRA BIO, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 16, 2026
- 8-KMaterial eventJun 9, 2026
- 10-QQuarterly reportMay 12, 2026
- 8-KMaterial eventMay 11, 2026
- DEF 14AProxy statementApr 27, 2026
- 8-KMaterial eventApr 9, 2026
- 10-KAnnual reportMar 16, 2026
- 8-KMaterial eventMar 16, 2026
- 8-KMaterial eventJan 7, 2026
- 10-QQuarterly reportNov 10, 2025
- 8-KMaterial eventNov 10, 2025
- 8-KMaterial eventNov 6, 2025
- 8-KMaterial eventSep 5, 2025
- 8-KMaterial eventSep 2, 2025
- 8-KMaterial eventAug 18, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q4 2025 | Q2 2026 | $8.69 | $6.82 | -22% |
| Two Sigma Investments | Q3 2025 | open | $9.48 | $6.83 | -28% |
| Renaissance Technologies | Q3 2025 | open | $9.88 | $6.83 | -31% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.